Literature DB >> 16398746

Complications of plasma exchange in patients treated for clinically suspected thrombotic thrombocytopenic purpura-hemolytic uremic syndrome.

Mark A Howard, Lauren A Williams, Deirdra R Terrell, Deanna Duvall, Sara K Vesely, James N George.   

Abstract

Entities:  

Mesh：

Year:  2006        PMID： 16398746     DOI： 10.1111/j.1537-2995.2006.00687.x

Source DB:  PubMed          Journal:  Transfusion        ISSN： 0041-1132            Impact factor:   3.157


× No keyword cloud information.
  21 in total

1.  Decreasing frequency of plasma exchange complications in patients treated for thrombotic thrombocytopenic purpura-hemolytic uremic syndrome, 1996 to 2011.

Authors:  Sumit Som; Cassandra C Deford; Mandi L Kaiser; Deirdra R Terrell; Johanna A Kremer Hovinga; Bernhard Lämmle; James N George; Sara K Vesely
Journal:  Transfusion       Date:  2012-04-15       Impact factor: 3.157

2.  Short- and long-term effects of rituximab for the treatment of thrombotic thrombocytopenic purpura: four case reports.

Authors:  Futoshi Iioka; Daiki Shimomura; Toru Ishii; Yoshitomo Maesako; Kazuhiro Ohgoe; Fumihiko Nakamura; Shuji Matsuo; Hitoshi Ohno
Journal:  Int J Hematol       Date:  2012-08-10       Impact factor: 2.490

3.  Correction of murine ADAMTS13 deficiency by hematopoietic progenitor cell-mediated gene therapy.

Authors:  Pablo Laje; Dezhi Shang; Wenjing Cao; Masami Niiya; Masayuki Endo; Antoneta Radu; Nicole DeRogatis; Friedrich Scheiflinger; Philip W Zoltick; Alan W Flake; X Long Zheng
Journal:  Blood       Date:  2009-01-13       Impact factor: 22.113

4.  Effect of prophylactic cyclosporine therapy on ADAMTS13 biomarkers in patients with idiopathic thrombotic thrombocytopenic purpura.

Authors:  Spero R Cataland; Ming Jin; Shili Lin; Eric H Kraut; James N George; Haifeng M Wu
Journal:  Am J Hematol       Date:  2008-12       Impact factor: 10.047

5.  Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience.

Authors:  Paul Coppo; Michael Schwarzinger; Marc Buffet; Alain Wynckel; Karine Clabault; Claire Presne; Pascale Poullin; Sandrine Malot; Philippe Vanhille; Elie Azoulay; Lionel Galicier; Virginie Lemiale; Jean-Paul Mira; Christophe Ridel; Eric Rondeau; Jacques Pourrat; Stéphane Girault; Dominique Bordessoule; Samir Saheb; Michel Ramakers; Mohamed Hamidou; Jean-Paul Vernant; Bertrand Guidet; Martine Wolf; Agnès Veyradier
Journal:  PLoS One       Date:  2010-04-23       Impact factor: 3.240

Review 6.  Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura.

Authors:  J Evan Sadler
Journal:  Blood       Date:  2008-07-01       Impact factor: 22.113

7.  [A 42 year old patient with bilateral loss of sight and hypertension. Gemcitabine-associated thrombotic microangiopathy (TMA)].

Authors:  A Schmidt; N Schwella; U Helmchen; D von Renteln; K Caca
Journal:  Internist (Berl)       Date:  2008-08       Impact factor: 0.743

Review 8.  Pathogenesis and prognosis of thrombotic microangiopathy.

Authors:  Masaomi Nangaku; Hiroshi Nishi; Toshiro Fujita
Journal:  Clin Exp Nephrol       Date:  2007-06-28       Impact factor: 2.801

Review 9.  Thrombotic microangiopathy in haematopoietic stem cell transplantation: diagnosis and treatment.

Authors:  Cecilia M Choi; Alvin H Schmaier; Michael R Snell; Hillard M Lazarus
Journal:  Drugs       Date:  2009       Impact factor: 9.546

10.  AAV-mediated expression of an ADAMTS13 variant prevents shigatoxin-induced thrombotic thrombocytopenic purpura.

Authors:  Sheng-Yu Jin; Juan Xiao; Jialing Bao; Shangzhen Zhou; J Fraser Wright; X Long Zheng
Journal:  Blood       Date:  2013-03-20       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.